Promoting Repigmentation After Epidermal Cell Suspension Grafting and preVENTing the Loss of Melanocytes Using Topical Ruxolitinib for Vitiligo in Resistant Areas

NCT05872477 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Vitiligo

Interventions

DRUG: Ruxolitinib Topical
DRUG: Placebo

Sponsor

Centre Hospitalier Universitaire de Nice